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Background: Macrophages are key targets of HIV-1 infection. We have previously described that the expression
of CC chemokine ligand 2 (CCL2) increases during monocyte differentiation to macrophages and it is further
up-modulated by HIV-1 exposure. Moreover, CCL2 acts as an autocrine factor that promotes viral replication in
infected macrophages. In this study, we dissected the molecular mechanisms by which CCL2 neutralization inhibits
HIV-1 replication in monocyte-derived macrophages (MDM), and the potential involvement of the innate restriction
factors protein sterile alpha motif (SAM) histidine/aspartic acid (HD) domain containing 1 (SAMHD1) and apolipoprotein
B mRNA-editing, enzyme-catalytic, polypeptide-like 3 (APOBEC3) family members.
Results: CCL2 neutralization potently reduced the number of p24 Gag+ cells during the course of either productive or
single cycle infection with HIV-1. In contrast, CCL2 blocking did not modify entry of HIV-1 based Virus Like Particles, thus
demonstrating that the restriction involves post-entry steps of the viral life cycle. Notably, the accumulation of viral
DNA, both total, integrated and 2-LTR circles, was strongly impaired by neutralization of CCL2. Looking for correlates of
HIV-1 DNA accumulation inhibition, we found that the antiviral effect of CCL2 neutralization was independent of the
modulation of SAMHD1 expression or function. Conversely, a strong and selective induction of APOBEC3A expression,
to levels comparable to those of freshly isolated monocytes, was associated with the inhibition of HIV-1 replication
mediated by CCL2 blocking. Interestingly, the CCL2 neutralization mediated increase of APOBEC3A expression was type
I IFN independent. Moreover, the transcriptome analysis of the effect of CCL2 blocking on global gene expression
revealed that the neutralization of this chemokine resulted in the upmodulation of additional genes involved in the
defence response to viruses.
Conclusions: Neutralization of endogenous CCL2 determines a profound restriction of HIV-1 replication in primary
MDM affecting post-entry steps of the viral life cycle with a mechanism independent of SAMHD1. In addition, CCL2
blocking is associated with induction of APOBEC3A expression, thus unravelling a novel mechanism which might
contribute to regulate the expression of innate intracellular viral antagonists in vivo. Thus, our study may potentially lead
to the development of new therapeutic strategies for enhancing innate cellular defences against HIV-1 and protecting
macrophages from infection.
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Early after its discovery, it has been established that
HIV-1, like other retroviruses, infects not only CD4+ T
lymphocytes but also macrophages. The presence of
HIV-1-infected macrophages in vivo has been docu-
mented in various tissues, including brain, lung and gut
[1-10]. Although their precise contribution to the infec-
tion and pathogenesis of HIV-1 is still a matter of de-
bate, the importance of macrophages in these processes
is highlighted by their involvement in early-stage viral
transmission, persistence, and virus dissemination through-
out the body of the host [11,12]. Once infected, macro-
phages promote rapid virus dissemination by transmitting
viral particles to CD4+ T cells via a transit “virological
synapse” [13]. As macrophage has the ability to cross
the blood-tissue barrier and to migrate into tissues,
HIV-infected macrophages are potent agents for viral
delivery to all tissues and organs. Macrophages are con-
sidered as viral reservoirs because they are long-lived
cells resistant to the cytopathic effects of HIV-1 and
“hide” the virus in safe intracellular compartments [14].
This allows maintaining a hidden HIV-1 reservoir for
ongoing infection, hardly eradicable by currently avail-
able pharmacological therapies [15]. Therefore, efforts
directed to defining the mechanisms and factors con-
trolling HIV-1 replication in macrophages may provide
the basis for devising new, long-term successful treat-
ment of infected individuals [11].
Chemokines and their receptors are deeply involved in
the control of HIV-1 infection [16]. In addition to
CCR5- and CXCR4-binding chemokines interfering with
HIV-1 infection at the entry level, other chemokines
have been shown to play a role in this infection [17]. In
particular, CC chemokine ligand 2 (CCL2; formerly mono-
cyte chemotactic protein-1, MCP-1) is induced during
several human acute and chronic viral infections [18,19].
In addition to HIV-1 infection [20,21], virus-derived pro-
teins such as gp120 [22], Nef [23], matrix protein p17 [24]
and transactivator protein Tat [25,26] increase the expres-
sion and release of this chemokine. CCL2 is produced by
a variety of cell types, with monocytes/macrophages re-
presenting the major source among leukocytes [18,19].
Although the precise contribution of CCL2 in HIV-1 infec-
tion and pathogenesis remains to be established, growing
evidence suggests that it may play important roles in these
processes [18]. We previously found that CCL2 is up-
regulated during monocyte differentiation to macrophages
and it is further increased upon HIV-1 infection or expos-
ure to viral proteins. Furthermore, this chemokine acts as
an autocrine factor that sustains viral replication in HIV-1
infected cells [21]. However, the mechanism(s) by which
CCL2 fosters HIV-1 production remains to be elucidated.
A variety of host cell factors can interfere with HIV-1
replication [27-29]. Among these, the protein sterile alphamotif (SAM) histidine/aspartic acid (HD) domain contain-
ing 1 (SAMHD1) was recently identified as a restriction
factor in myeloid cells [30,31]. SAMHD1 is a dGTP-
regulated deoxynucleotide triphosphates (dNTP) hydro-
lase that limits the pool of dNTP available for reverse
transcription, therefore reducing HIV-1 infection of
myeloid cells [32-34]. Recently, it has been shown that
SAMHD1 can restrict HIV-1 infection also through deg-
radation of viral RNA [35]. In addition to SAMHD1,
members of the apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3 (APOBEC3; A3) family of
cytidine deaminases are potent innate intracellular viral
antagonists which restrict HIV-1 replication in target cells
[36-38]. The human genome encodes seven A3 genes
(A3A, A3B, A3C, A3D/E, A3F, A3G and A3H) [39]. A3
proteins are widely expressed in hematopoietic cell popu-
lations, including T cells, B cells and myeloid cells [40,41].
In particular, A3A and A3G are critical for monocyte re-
sistance to infection and their decreased expression during
macrophage differentiation results in a permissive target
cell population [42]. Beyond the well known capacity of
type I interferon to induce the expression of some A3
family members [43], little is known concerning the fac-
tors and mechanisms regulating the expression of these
enzymes in myeloid cells. Thus, their identification might
offer great opportunities to prevent HIV-1 from infecting
and persisting in macrophages.
In this study, we aimed at dissecting the molecular
mechanisms by which CCL2 blocking restricts HIV-1
replication in macrophages. We report that neutralization
of this chemokine reduces the number of infected macro-
phages, without affecting viral entry, and impairs viral
DNA accumulation. Interestingly, whereas SAMHD1 ex-
pression and function are not altered by CCL2 blocking, a
strong and selective induction of A3A expression is asso-
ciated with the CCL2 neutralization-mediated restriction
of HIV-1 replication. Therefore, our study highlights the
potential of targeting this chemokine to impair early steps
of HIV-1 replication and to strengthen innate intracellular
pathways to thwart HIV-1 infection.
Results
Neutralization of endogenous CCL2 reduces the proportion
of HIV-1 infected MDM
In our previous studies we found that CCL2 neutralization
reduced the release of p24 Gag antigen in HIV-1 infected
monocyte-derived macrophages (MDM) [21]. To examine
the mechanisms by which CCL2 blocking inhibits HIV-1
replication in these cells, experiments were performed to
assess whether neutralization of this chemokine affected
the total number of infected cells. Toward this aim, MDM
cultures established from several donors were exposed for
20 h to anti-CCL2 or control antibody (Ab) and then
challenged with HIV-1BaL. The proportion of infected cells
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after permeabilization and staining for intracellular p24
Gag. A marked variability in the percentage of p24 Gag+
cells was observed among donors, ranging from 2.4 to
77.3% [median value: 28.0 ± 5.4 (SE); n = 22]. Despite this
variability, treatment with anti-CCL2 Ab strongly reduced
the percentage of p24 Gag+ cells in all the donors analyzed
(Figure 1A). In spite of an occasional effect of control Ab
on this parameter, anti-CCL2 Ab significantly reduced the
proportion of p24 Gag+ cells with respect to control Ab
treatment in all the donors analyzed. In particular, as
shown in Figure 1B, exposure to anti-CCL2 Ab reduced
the fraction of p24 Gag+ cells to 0.23 ± 0.04 (SE) fold com-
pared to control Ab treatment (p < 0.001). In keeping with
previous results [21], the reduction of infected cells was
associated with a marked inhibition of the release of p24
Gag in culture medium of MDM treated with anti-CCL2
Ab [0.19 ± 0.05 (SE) fold vs. control Ab; p < 0.001]. Fur-
thermore, an increase of CCL2 production following HIV-
1 infection was found in these donors. In particular, at
14 days post-infection the median CCL2 secretion in
uninfected cells was 8,410.9 ± 1,027.5 (SE) pg/ml, whereas
it increased to 18,982.9 ± 2,102.1 (SE) pg/ml (p < 0.001)
upon infection with HIV-1. Measurement of CCL2 release
in Ab treated cultures showed that the anti-CCL2 Ab
effectively neutralized the chemokine produced by MDM
(Additional file 1: Figure S1A).
We then investigated whether CCL2 blocking also
inhibited a single cycle HIV-1 infection. To this aim, we
used a recombinant virus, mutated in the env gene and
pseudotyped with Vesicular Stomatitis Virus G-protein
(VSV-G), which enters macrophages through a CD4/
CCR5-independent pathway and completes only a single
round of infection [44]. MDM exposed for 20 h to anti-
CCL2 or control Ab were challenged with (VSV-G)
HIV-1 and the percentage of p24 Gag+ cells was mea-
sured 3 days post-infection. The percentage of p24 Gag+
cells ranged from 17.1 to 77.5% [median value: 49.4 ±
24.7 (SE); n = 4]. Despite this variability, treatment with
anti-CCL2 Ab markedly reduced the percentage of p24
Gag+ MDM in all the donors analyzed (Figure 1C). In
particular, the proportion of p24 Gag+ cells following
treatment with anti-CCL2 Ab was reduced to 0.41 ± 0.16
(SE) fold with respect to untreated cells (p < 0.05). Con-
trol experiments were performed in the presence of the
reverse-transcriptase inhibitor zidovudine (AZT) to en-
sure that the detected fraction of infected cells was not
biased by cell membrane-attached p24 Gag. As expected,
a strong reduction in the fraction of p24 Gag+ cells was
observed in the presence of AZT. Measurement of
CCL2 release in Ab treated cultures showed that the
anti-CCL2 Ab effectively neutralized the chemokine pro-
duced by MDM also in these conditions (Additional
file 1: Figure S1B).Endogenous CCL2 neutralization does not affect entry of
HIV-1 in MDM
We then investigated whether CCL2 blocking-mediated
inhibition of HIV-1 replication could be due to reduced
viral entry in MDM. To this aim, we used fluorescent
HIV-1-based Viral Like Particles (VLPs) pseudotyped
with either VSV-G or R5 HIV-1 Env from the Ada strain
(VSV-G-VLPs and Ada-VLPs, respectively), which has
been previously shown to enter different types of cells
with high efficiency [45,46]. MDM exposed for 20 h to
anti-CCL2 or control Ab were challenged with VLPs and
the percentage of GFP+ cells was measured after 2 and
4 h of incubation at 37°C. Control experiments were
performed by incubating cells at 4°C. As shown in
Figure 2A, about 50% of MDM were GFP+ following
2 h of incubation with VSV-G-VLPs, whereas viral entry
driven by Ada-VLPs was less efficient and rendered fluor-
escent about 10% of the cells. Similar proportions of GFP+
cells were detected following 4 h of incubation at 37°C.
Interestingly, treatment with anti-CCL2 or control Ab did
not modify entry of either Ada-VLPs or VSV-G-VLPs
(Figure 2A and Additional file 2: Figure S2). Control
experiments were performed in the presence of sol-
uble LDLR or T20 to block fusion of VSV-G-VLPs or
Ada-VLPs, respectively [47,48]. As expected, a strong
reduction in the fraction of GFP+ cells was observed
in these conditions, thus confirming that the fluores-
cence detected in target cells indeed relied on authentic
viral fusion events (Figure 2B). Microscopic analysis of
target cells showed a strong fluorescence associated
with VSV-G-VLPs challenged MDM, while a signifi-
cant lower signal was detected in the cells challenged
with Ada-VLPs (Figure 2C). Finally, the internalization
of VLPs was further confirmed by confocal microscope
analysis (Figure 2D).
To verify that anti-CCL2 Ab did not affect reverse tran-
scriptase (RT) activity and early post-entry events, we
evaluated HIV-1 DNA synthesis by semi-quantitative PCR
assay at 24 h post-infection. Primers were used as de-
scribed to amplify different regions of the HIV genome
and to estimate the extent of reverse transcription at three
replicative steps that occur in subsequent order during re-
verse transcription: R-U5, initial minus strand synthesis;
R-PB, initial plus-strand synthesis up to the PB region;
and R-gag, complete minus-strand synthesis [49]. Results
indicate that the presence of anti-CCL2 Ab did not
influence HIV-1 DNA synthesis in the infected cells early
post-infection (Additional file 3: Figure S3A). These re-
sults were confirmed by further evaluation of the HIV-1
DNA intermediates by a quantitative PCR Real Time assay
(Additional file 3: Figure S3B).
These results clearly demonstrate that CCL2 blocking
did not show any interference in both entry and RT
activity.
Figure 1 (See legend on next page.)
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Figure 1 Neutralization of endogenous CCL2 reduces the proportion of HIV-1 infected MDM. MDM were treated with anti-CCL2 or control
Ab (2.5 μg/ml) for 20 h. (A, B) Cells were then infected with HIV-1BaL (3000 TCID50 per well) as described in Methods. After 14 days, cells were
recovered and HIV-1 Gag expression was evaluated by flow cytometry. Values indicate the percentage of p24 Gag+ cells for each sample. In A,
the results from 3 representative donors out of 22 tested are shown. In B, data represent mean values (+SE) of the results obtained with all the
donors analyzed. ***p < 0.001 (anti-CCL2 Ab vs. control Ab). (C) Cells were challenged with (VSV-G) HIV-1 (250 ng CAp24 equivalent per 105 cells)
in a single-round infectivity assay. Some cultures were also treated with AZT (10 μM). The percentage of p24 Gag+ cells was assessed by flow
cytometry 3 days after infection. Data represent mean values (+SE) of the results obtained with MDM from 4 different donors. *p < 0.05
(anti-CCL2 Ab and AZT vs. nil).
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accumulation in MDM
To further investigate the mechanisms underlying the
inhibition of HIV-1 replication associated with CCL2
neutralization in MDM, we quantified the levels of viral
DNA that accumulated at different time points post-
infection. Toward this aim, MDM exposed for 20 h to
anti-CCL2 or control Ab were challenged with HIV-
1BaL, and total viral DNA was quantified 4 and 7 days
post-infection. A marked variability was observed in the
levels of total HIV-1 DNA among donors. In particular,
in untreated MDM the values of viral DNA copies
per 106 cells ranged from 8,301.6 to 155,264.4 [median
value: 73,824.5 ± 37,301.1 (SE)] and from 69,140.2 to
258,503.4 [median value: 137,845.2 ± 42,908.1 (SE)] at 4
and 7 days post-infection, respectively (n = 4). Despite this
variability, treatment of MDM with anti-CCL2 Ab led to a
significant decrease in the accumulation of HIV-1 DNA
copies at both time points (Figure 3A), with a more pro-
found reduction of viral DNA levels at 7 days post-
infection. These experiments also revealed that CCL2
neutralization strongly influenced the kinetics of HIV-1
DNA accumulation. In fact, as shown in Additional file 4:
Figure S4, a marked increase of total viral DNA level was
observed in both untreated and control Ab treated cells at
7 vs. 4 days post-infection [5.40 ± 2.49 (SE) and 5.60 ± 2.69
(SE) fold, respectively]. In contrast, in anti-CCL2 Ab
treated MDM the levels of HIV-1 DNA at 7 days post-
infection were similar to those found 4 days after infection
[0.96 ± 0.45 (SE) fold].
We next examined the concentration-dependency of
the effect of anti-CCL2 Ab on HIV-1 DNA levels after
7 days of infection. As shown in Figure 3B, the viral
DNA decrease caused by anti-CCL2 Ab was concentra-
tion dependent and statistically significant at all the con-
centrations tested [0.08 ± 0.03 (SE), 0.12 ± 0.04 (SE) and
0.37 ± 0.07 (SE) at the concentrations of 2.5 (p < 0.001),
1.25 (p < 0.01) and 0.625 (p < 0.05) μg/ml, respectively;
n = 3]. The decrease of HIV-1 DNA induced by the max-
imal Ab concentration was significantly higher with re-
spect to that observed at the lowest one (p < 0.01). In
spite of an occasional effect of control Ab on the level of
HIV-1 DNA, the presence of anti-CCL2 Ab significantly
reduced the amount of viral DNA copies accumulated7 days post-infection with respect to control Ab treat-
ment [0.26 ± 0.09 (SE) fold vs. control Ab; p < 0.001;
n = 13] (Figure 3C).
Furthermore, we observed that CCL2 neutralization
similarly affected the accumulation of different intra-
cellular forms of HIV-1 DNA. In particular, as shown in
Figure 3D, the presence of anti-CCL2 Ab significantly
reduced the amount of episomal 2-long terminal repeat
(2-LTR) DNA circles accumulated 7 days post-infection
with respect to control Ab treatment [0.26 ± 0.14 (SE)
fold vs. control Ab; p < 0.05; n = 3]. Finally, a marked re-
duction of integrated proviral DNA, as measured by
Alu-PCR, was also observed in anti-CCL2 Ab treated
MDM in comparison to control cells [0.28 ± 0.007 (SE)
fold vs. control Ab; p < 0.001; n = 4; Figure 3E].
Overall, these results clearly indicate that CCL2 neu-
tralization significantly impairs HIV-1 DNA accumulation.
SAMHD1 expression and function are not affected by
CCL2 neutralization in infected MDM
Searching for potential correlates of the post-entry
restriction of the HIV-1 life cycle mediated by CCL2
blocking in MDM, we firstly focused our attention on
SAMHD1, a host factor that restricts HIV-1 replication
in myeloid cells by either depleting dNTP levels below
those required for optimal synthesis of HIV-1 DNA or
degrading viral RNA [33,35]. Therefore, we performed
qPCR and Western blot analysis to evaluate SAMHD1
expression in both control and anti-CCL2 Ab treated
MDM at the time of HIV-1 infection (i.e., 20 h after
treatment). As shown in Figure 4A, treatment of MDM
with anti-CCL2 Ab did not significantly affect SAMHD1
gene expression. These results were further confirmed
by Western blot analysis. As shown in Figure 4B, SAMHD1
protein was highly expressed in control MDM, and
the presence of CCL2 Ab does not change either its
expression or the level of its phosphorylation, that
has been shown to regulate the RNase activity of this
enzyme [35]. Similarly, SAMHD1 protein expression
was not affected by CCL2 blocking in HIV-1-infected
MDM (Figure 4C). These findings strongly suggest that
the mechanism of inhibition of HIV-1 replication induced
by anti-CCL2 Ab do not involve modulation of SAMHD1
expression or phosphorylation.
Figure 2 (See legend on next page.)
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Figure 2 Endogenous CCL2 neutralization does not affect HIV-1 entry in MDM. (A) MDM were treated with anti-CCL2 or control Ab
(2.5 μg/ml) for 20 h and then challenged with Null-VLPs, VSV-G-VLPs or Ada-VLPs (1 μg of CAp24 equivalent per 105 cells) as described in Methods.
After 2 and 4 h, the percentage of GFP+ cells was assessed by flow cytometry. Data represent mean values (+SE) of the results obtained with MDM
from 4 different donors. (B) MDM were treated as in A and then challenged with VSV-G-VLPs or Ada-VLPs either in the presence or in the absence of
soluble LDLR (5 μg/ml) or T20 (1 μg/ml). The results obtained with 1 out of 2 different donors analyzed are shown. (C) Fluorescence microscope
analysis of MDM 2 hours after the challenge with Null-VLPs, VSV-G-VLPs or Ada-VLPs. Phase-contrast micrographs of the same fields are shown on the
left. Bars mark 100 μm. (D) Confocal microscope analysis of MDM 2 hours after the challenge with Null-VLPs, VSV-G-VLPs or Ada-VLPs. Images represent
a Z-projection of 5 optical sections taken near the middle of the cell nucleus. VLP signal is shown in green, while nuclei are stained with DAPI (blue).
Bars mark 10 μm.
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activity could be regulated by CCL2 blocking. To this
aim, we evaluated the effect of dNTPs supply in our ex-
perimental conditions. MDM exposed for 20 h to anti-
CCL2 or control Ab were infected with HIV-1BaL either
in the absence or in the presence of dNTPs, and the
percentage of p24 Gag+ cells was assessed 14 days
post-infection. As expected, exogenous dNTPs increased
the percentage of p24 Gag+ cells in all conditions
(Additional file 5: Figure S5). Interestingly, the percentage0
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Figure 4 SAMHD1 expression and function are not affected by CCL2 neutralization in MDM. (A) MDM were treated with anti-CCL2 or
control Ab (2.5 μg/ml) for 20 h. Total RNA was then extracted, retrotranscribed, amplified and the 2ΔΔCt values for SAMHD1 transcripts were calculated
as described in Methods. (B) MDM were treated as in A and SAMHD1 protein expression and phosphorylation in whole cell extracts were detected by
western blot. Actin was used as house-keeping gel loading control. (C) MDM were treated as in A and then infected with HIV-1BaL (3000 TCID50 per
well) as described in Methods. Cells were lysed 14 days after infection and SAMHD1 protein expression in whole cell extracts was detected by western
blot. Actin was used as house-keeping control. (D) MDM were treated and infected as in C either in the absence or in the presence of dNTPs (1.5 mM)
as described in Methods. After 14 days, cells were recovered and HIV-1 Gag expression was evaluated by flow cytometry. (E) MDM were treated as in
A and then challenged with LV/Vpx expressing GFP (2 × 106 TU per 106 cells). The proportion of GFP+ cells was determined 3 days post-infection by
flow cytometry. The effect of Vpx on SAMHD1 protein expression is shown in the inset. In A and E, data represent mean values (+SE) of the results
obtained with 4 different donors. In B, C and D, the result from a single representative experiment out of 4 independently performed is shown.
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anti-CCL2 or control Ab were challenged with LV/Vpx,
and the proportion of GFP+ cells was determined 3 days
post-infection by flow cytometry. As shown in Figure 4E,
a significant reduction in the fraction of GFP+ cells
was observed in the cultures treated with anti-CCL2
Ab. As expected, the presence of Vpx strongly reduced
SAMHD1 protein expression (Figure 4E, inset), thus con-
firming that the observed inhibition is SAMHD1 inde-
pendent. These results indicate that CCL2 neutralization
is still capable of inhibiting HIV-1 infection in MDM
when SAMHD1 expression is strongly reduced.
Therefore, neither altered SAMHD1 expression nor
function likely account for the CCL2 neutralization-
dependent restriction of HIV-1 replication in MDM.
Neutralization of CCL2 selectively up-regulates A3A
expression in MDM
We next focused our attention on the A3 family of
restriction factors in that some of these proteins restrict
the infectivity of HIV-1 primarily by hyper mutating
viral cDNA and inhibiting reverse transcription and inte-
gration, thus impairing viral DNA accumulation [50,51].
Therefore, we performed qPCR analysis for A3 family
member transcripts in both control and anti-CCL2 Ab
treated MDM at the time of HIV-1 infection (i.e., 20 h
after treatment). As shown in Figure 5A, treatment of
MDM with anti-CCL2 Ab strongly increased the accu-
mulation of A3A transcripts, whereas A3B, A3C, A3D,
A3F, A3G and A3H mRNA levels were not significantly
affected. We further investigated the consequence of
CCL2 neutralization on A3A mRNA expression by using
MDM obtained from additional donors. The effect of
CCL2 blocking on A3A transcripts was consistently ob-
served in all the donors analyzed. In particular, as shown
in Figure 5B, a 30.45 ± 4.70 (SE) fold increase in A3A
mRNA level was observed after 20 h of exposure to
anti-CCL2 Ab (p < 0.01 vs. nil or control Ab; n = 6).
We then studied whether the increase in A3A mRNA
levels corresponded to induction of A3A protein expres-
sion. As previously reported by other groups [52,53],
two isoforms of A3A can be detected by Western blot
analysis in MDM (Figure 5C), with some variability intheir constitutive expression among donors. In particu-
lar, some donors did not constitutively express both
A3A isoforms, whereas others expressed the isoform
with a lower molecular weight (data not shown). Despite
this variability, anti-CCL2, but not control Ab, resulted
in a strong induction of both A3A isoforms expression
as measured after 20 h of incubation (Figure 5C). Inter-
estingly, A3A expression levels induced by CCL2 block-
ing were comparable to those of freshly isolated
monocytes (Figure 5C and D).
Furthermore, to exclude any effect of CCL2 neutra-
lization on A3G expression, we analyzed A3G protein
levels by Western blot analysis. As shown in Additional
file 6: Figure S6, MDM did not express the low molecular
mass form of A3G (~46 kDa) either in control conditions
or after incubation with anti-CCL2 Ab, whereas this
protein was induced by IFN-β, as already reported by
others [54].
It has been previously reported that IFNs are potent
inducers of A3 family member expression [43]. In par-
ticular, type I IFN has been shown to induce A3A ex-
pression in monocytes/macrophages [42,52,53]. We thus
investigated whether the induction of A3A expression
elicited by CCL2 neutralization was mediated by type I
IFN. To this aim, endogenous IFN, eventually produced
in MDM exposed to anti-CCL2 Ab, was neutralized by
means of Ab to IFN-α or IFN-β. As shown in Figure 5E
and F, the presence of these Abs did not modify
A3A protein expression induced by CCL2 blocking.
In keeping with this result, type I IFN was not de-
tected in the supernatants of anti-CCL2 Ab-treated
MDM as measured by a cytopathic effect reduction
assay (data not shown). These results indicate that
A3A induction by CCL2 neutralization is type I IFN
independent.
Moreover, we investigated whether A3A expression
was specifically induced by CCL2 blocking. To this aim,
we targeted other CC-chemokines which are expressed
by macrophages and are further induced by HIV-1
infection of these cells [17]. As shown in Figure 5G,
treatment of MDM with anti-CCL3, anti-CCL4 and anti-
CCL5, as well as control Ab, did not affect A3A protein
expression.
Figure 5 Endogenous CCL2 neutralization induces A3A expression in MDM. (A-B) MDM were treated with anti-CCL2 or control Ab (2.5 μg/ml).
After 20 h, total RNA was extracted and A3 expression was analyzed by qPCR and expressed as 2ΔΔCt values. In A, the result from 1 representative
donor of 3 tested is shown. In B, data represent mean values (+SE) of the results obtained with 6 donors. **p< 0.01 (anti-CCL2 Ab vs. nil or control Ab).
(C-D) MDM were treated as in A, and A3A protein expression was detected by western blot and compared to those of freshly isolated monocytes from
the same donor. In C, the result from 1 representative donor of 5 analyzed is shown. In D, the ratio of A3A to actin was determined by densitometry,
and graph shows the mean of the fold relative to monocytes (+SE) of the 5 donors tested. *p< 0.05 (anti-CCL2 Ab vs. nil); ***p< 0.001 (nil vs. monocyte).
(E-F) MDM were treated as in A in the presence or absence of IFN-α (1:750) or IFN-β (1:250) neutralizing serum, and A3A protein expression was detected
by western blot. In E, the result from 1 representative donor of 5 tested is shown. In F, the ratio of A3A to actin was determined by densitometry, and
graph shows the mean of the fold relative to nil (+SE) of the 5 donors tested. (G) MDM were treated with anti-CCL2, anti-CCL3, anti-CCL4, anti-CCL5 and
control Ab (2.5 μg/ml). After 20 h, cells were lysed and A3A protein expression was detected by western blot. The result from 1 representative donor of
6 tested is shown. (H) MDM were treated as in A and then infected with HIV-1BaL. After 14 days, A3A protein was detected by western blot. The result
from 1 representative donor of 6 tested is shown.
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CCL2 neutralization also occurred in HIV-1 infected
MDM. Therefore, MDM exposed for 20 h to anti-CCL2
or control Ab were infected with HIV-1BaL and A3A ex-
pression was analyzed 14 days post-infection by Western
blot analysis. As shown in Figure 5H, A3A was notdetected in MDM infected with HIV-1 either in the
absence or in the presence of control Ab, whereas this
protein was highly expressed in infected cells maintained
in the presence of anti-CCL2 Ab.
Since controversial data have been reported by different
groups concerning the effect of Vpx on A3A expression
Sabbatucci et al. Retrovirology  (2015) 12:4 Page 11 of 22[55-57], we analyzed the expression of this protein in
MDM challenged with LV/Vpx. As shown in Additional
file 7: Figure S7, unlike SAMHD1 expression, the pres-
ence of Vpx in lentiviral preparations did not affect A3A
expression.
Effect of the timing of anti-CCL2 Ab addition on HIV-1
replication restriction and A3A expression
We then investigated whether the timing of anti-CCL2
Ab addition to MDM was important for the impairment
of HIV-1 replication. Therefore, MDM were treated with
anti-CCL2 Ab 20 h before or at the time of infection,
and viral DNA accumulation and the proportion of p24
Gag+ cells were measured 7 and 14 days post-infection,
respectively. As shown in Figure 6A, a decrease of HIV-
1 DNA accumulation was observed in MDM exposed to
anti-CCL2 Ab both 20 h before or at the time of infec-
tion [0.10 ± 0.02 (SE) and 0.16 ± 0.07 (SE) fold vs. control
Ab, respectively (p < 0.001); n = 3]. Furthermore, addition
of anti-CCL2 Ab concomitantly with HIV-1 infection
also significantly reduced the percentage of p24 Gag+
cells, although to a lesser extent with respect to what
observed in MDM exposed to anti-CCL2 Ab 20 h before
infection [0.23 ± 0.08 (SE) and 0.47 ± 0.19 (SE) fold vs
control Ab in MDM treated 20 h before (p < 0.001)
or at the time of infection (p < 0.05), respectively; n = 7]
(Figure 6B).
Finally, we determined whether A3A expression was
also induced in infected MDM exposed to anti-CCL2 Ab
at the time of infection. Notably, as shown in Figure 6C,
A3A protein was induced in these experimental condi-
tions at similar levels to those observed in cells exposed to
anti-CCL2 Ab 20 h before infection.
Therefore, these results further highlights the association
between A3A expression and the restriction of HIV-1 rep-
lication induced by neutralization of endogenously released
CCL2.
Transcriptome analysis of the effect of CCL2
neutralization on global gene expression in MDM
To characterize the effect of CCL2 blocking on global
gene expression, MDM from two different donors were
exposed to anti-CCL2 Ab, and compared to control sam-
ples. Cells were collected at 20 h post-treatment and total
RNA was isolated, subjected to poly(A) selection followed
by reverse transcription, generation of cDNA libraries,
and sequencing.
We performed differential expression analysis using
DESeq2 [58] and identified 194 genes upregulated upon
treatment and 117 downregulated (FDR < 0.01 and fold
change > 2) (Additional file 8: Table S1).
In keeping with the data shown in Figure 5, we found
that the A3A gene was more highly expressed in the 2
treated donors analyzed, compared to their controls(Figure 7A). In order to gain further insight into the spe-
cific categories of genes whose expression is changed upon
treatment, we performed annotation and pathway analysis.
According to Ensembl75 annotation, 111 genes were de-
tected in our RNAseq data to be annotated with the GO
biological term “defense response to virus” (GO:0051607)
and 24 out of these were more than 2 fold up in MDM
treated with anti CCL2 Ab for 20 h with respect to control
cells (Figure 7B). More GO annotation was done to our
194 upregulated genes using DAVID v6.7 [59,60] and
these genes were significantly enriched in GO biological
process terms GO:0009615 ~ response to virus (p value =
6.19E-09) and GO:0004587 ~ innate immune response
(p value = 7.55E-07) (Additional file 9: Table S2).
Besides A3A, the Mx2 gene was among the genes up
modulated by CCL2 in Figure 7B. Mx2 is a type I IFN-
induced protein that has been recently shown to restrict
HIV-1 replication by inhibiting the nuclear accumulation
and integration of HIV-1 reverse transcripts [61]. We
thus analyzed the effect of CCL2 neutralization on the
expression of Mx2 gene by RT-qPCR in MDM obtained
from additional donors. As shown in Figure 8A, expos-
ure of MDM to anti-CCL2 Ab induced an increase in
Mx2 transcript accumulation that was considerably
lower than that elicited by IFN-α. We thus analyzed
Mx2 protein levels by Western blot analysis. As shown
in Figure 8B and C, the expression of this protein was
not modified by CCL2 neutralization, whereas it was
induced by IFN-α.
Discussion
CCL2 is a potent pro-inflammatory chemokine induced
during HIV-1 infection and believed to be one of the key
factors driving chronic inflammation and tissue damage
in infected individuals [18,19]. Studies conducted thus
far have shown a multifaceted impact of CCL2 in HIV-1
pathogenesis and disease progression. In particular, CCL2,
mainly produced by monocytes/macrophages both in vitro
and in vivo, recruits CCR2+CD4+ T lymphocytes and
monocytes/macrophages, which represent key target cells
for HIV-1 infection. This chemokine also enhances viral
replication in T cells by increasing CXCR4 expression and
HIV-1 entry [62]. In vivo, high CCL2 levels in plasma and
cerebrospinal fluid of HIV-infected individuals correlate
with viral load [63-66]. Moreover, a genetic polymorphism
in the CCL2 gene (2518G/A), linked to an increased pro-
duction of the protein, is associated with increased risk of
HIV-1 infection, disease progression and development
of HIV-associated dementia [67]. Finally, the increase
in plasma viremia observed in acutely HIV-infected indi-
viduals is associated with a rapid and sustained elevation
in CCL2 plasma levels [68].
We have previously found that CCL2 expression was up-
regulated during monocyte differentiation to macrophages
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Figure 6 Effect of the timing of anti-CCL2 Ab addition on HIV-1 replication and A3A expression. MDM were treated with anti-CCL2 or
control Ab (2.5 μg/ml) 20 h before or at the time of infection with HIV-1BaL (3000 TCID50 per well) as described in Methods. (A) Total DNA was
extracted 7 days after infection and the amount of total HIV-1 DNA (copies/106 cells) was determined by qPCR. Data represent mean values (+SE)
of the results obtained with 3 different donors. (B) Cells were recovered 14 days after infection and HIV-1 Gag expression was evaluated by flow
cytometry. Data represent mean values (+SE) of the results obtained with 7 different donors. *p < 0.05; ***p < 0.001. (C) Cells were lysed 14 days after
infection, and A3A protein expression in whole cell extracts was detected by western blot. Actin was used as house-keeping control. The ratio of A3A
to actin protein was determined by densitometry, and graph shows the fold relative to control. The result from one representative experiment of 4
independently performed is shown.
Sabbatucci et al. Retrovirology  (2015) 12:4 Page 13 of 22and it was further increased by HIV-1 infection; conversely,
endogenously released CCL2 promoted HIV-1 replication
[21,69]. Consistently, infection of MDM with HIV-1 in the
presence of anti-CCL2 Ab resulted in a potent inhibition
of p24 Gag Ag release with respect to control cells, in the
intracellular accumulation of this viral antigen and in re-
markable changes in cell morphology and size [21]. Thus,
CCL2 may represent an autocrine factor important for en-
hancing virion production likely by affecting the macro-
phage cytoskeleton. The present study indicates that
additional, early post-entry steps of the HIV-1 life cycleA B
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Figure 7 Transcriptome analysis of the effect of CCL2 neutralization.
RNA was then extracted, subjected to poly(A) selection followed by reverse tr
DESeq2 normalized counts of the A3A gene following 20 h exposure to anti-C
donors. Dots were colored by donors. (B) Heatmap of 24 defense-response-to
the 20 h control MDM. Heatmap were made by GENE-E (http://www.broadinare also impaired upon CCL2 blocking. In fact, we report
here that neutralization of CCL2 potently reduces the pro-
portion of p24 Gag+ cells during the course of either a
productive infection with R5 HIV-1BaL or a single cycle in-
fection with (VSV-G) HIV-1. Since neither HIV-1 based
VLP entrance nor reverse transcription immediate prod-
ucts levels are affected by CCL2 blocking, the mechanism
of CCL2 neutralization-mediated restriction occurs inde-
pendently of HIV-1 entry and RT activity. Conversely,
CCL2 blocking potently limits the accumulation of
viral DNA, both total, integrated and 2-LTR circles.relative
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MDM were treated or not with anti-CCL2 Ab (2.5 μg/ml) for 20 h. Total
anscription, generation of cDNA libraries, and sequencing. (A) Dotplot of
CL2 Ab. Each condition has two biological replicates collected from two
-virus genes which are upregulated two-fold in 20 h anti-CCL2 Ab versus
stitute.org/cancer/software/GENE-E).
Figure 8 Effect of CCL2 neutralization on Mx2 expression. MDM were treated with anti-CCL2 or control Ab (2.5 μg/ml) or IFN-α (1000 U/ml)
for 20 h. (A) Total RNA was extracted, retrotranscribed, amplified and the 2ΔΔCt values for Mx2 transcripts were calculated as described in Materials
and Methods. The result from a single representative experiment of 3 independently performed is shown. (B) Cells were lysed and Mx2 protein
expression in whole cell extracts was detected by western blot. The result from a representative donor out of 6 analyzed is shown. (C) Densitometric
analyses of Mx2 expression performed on immunoblotting of MDM extracts from the 6 different donors analyzed. The graph shows the ratio of Mx2
to actin OD determined by densitometry. **p < 0.01 (IFN-α vs. nil).
Sabbatucci et al. Retrovirology  (2015) 12:4 Page 14 of 22In the present study we also provide evidence that
endogenous CCL2 may represent an autocrine factor
acting as a negative regulator of A3A expression in macro-
phages. In fact, targeting CCL2 induces A3A mRNA and
protein expression to levels observed in freshly isolatedmonocytes. This effect is specific for A3A among the A3
family of cytidine deaminases, since the expression of the
other A3 enzymes, including the most characterized anti-
HIV protein A3G, is not induced by CCL2 blocking. Inter-
estingly, the increase of A3A expression elicited by CCL2
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IFN. The identification of an IFN independent pathway of
A3A induction is of significance, particularly in the con-
text of viral infection. Most viruses, including HIV-1, are
known to evade the host immune response by blocking
IFN-mediated anti-viral responses [70]. Intriguingly, it has
been shown that SIV infected astrocytes produce CCL2
that binds to the CCR2 receptors on macrophages result-
ing in suppression of specific IFN stimulated genes [71].
Our finding, showing that the A3A antiviral response can
be activated through a mechanism other than the IFN-
driven one, unravels a novel pathway which may contrib-
ute to regulate the expression of this enzyme in vivo.
In addition to CCL2, other CC chemokines, namely
CCL3, CCL4 and CCL5, are constitutively released by
MDM and their production can be further increased
following HIV-1 infection of these cells [17]. Our data in-
dicate that neutralization of these chemokines does not
affect A3A protein levels. Thus, modulation of A3A ex-
pression seems to be a CCL2 specific task and not a
general function of chemokines. CCR2 is the only CCL2
receptor described thus far. Two different isoforms of this
receptor, named a and b, have been identified. They re-
present alternatively spliced variants of a single gene that
differ only in their carboxyl tails. In a previous study we
demonstrated that monocyte differentiation to macro-
phages resulted in a decrease of CCR2 mRNA, particularly
the b isoform, as well as of CCR2 levels at the plasma
membrane. The decrease of CCR2 expression was associ-
ated with a reduced biological response of MDM to CCL2
in terms of calcium flux and migration [69]. In the present
study, the role of CCR2 in the CCL2-mediated modulation
of A3A expression was not investigated. However, we
speculate that low levels of CCR2 expression could medi-
ate the observed phenotype. Furthermore, both increased
CCR2 expression and enhanced response to CCL2 have
been described in HIV-1-infected leukocytes by other
groups [72,73]. Thus, it cannot be excluded that enhanced
CCR2 expression in HIV-1 infected macrophages could
contribute to the observed effects on viral replication and
A3A expression. To our knowledge, this is the first study
showing that an endogenous chemokine can act as a nega-
tive regulator of A3 protein expression. In this regard, pre-
vious studies reported that triggering of CCR5 or CCR6
by CCL3 and HSP70 or CCL20 and human β-defensin 2,
respectively, supported A3G expression. Interestingly, in
these studies the increase in A3G levels was associated
with inhibition of HIV-1 replication in CD4+ T lympho-
cytes and dendritic cells (DC) [74,75].
Since the identification of A3 cytidine deaminases as
HIV-1 antiviral factors, a considerable amount of studies
have explored the role of these proteins in the pathogen-
esis of HIV-1 infection and the underlying mechanisms
of action. Cells belonging to the myeloid lineage expressall members of the A3 family, but A3A is the only one
restricted to these cells among the white blood cells tar-
gets of HIV-1 [40,41]. A3A shares sequence and func-
tional homology with A3G and is a potent inhibitor of
retrotrasposons, Parvovirus and HTLV-1 [76,77]. Its role
as inhibitor of HIV-1 replication is controversial. In fact,
although past studies indicated that A3A does not exert
an anti-HIV activity in established cell lines in which it is
ectopically expressed [36], more recent studies revealed
that an anti-HIV activity is explicit only in cells in which
A3A is naturally expressed, i.e. myeloid cells. In this re-
gard, Berger and colleagues reported that the pool of A3A
present in primary macrophages, DCs and differentiated
THP-1 cells (that mimic macrophages upon differenti-
ation) is directly capable of inhibiting incoming viruses at
the reverse transcription step. In that study, A3A expres-
sion has been shown to be up-regulated in MDM exposed
to HIV-1 [56]. We do not observe such effect in our in-
fected MDM cultures, in which A3A is increased over the
basal level only as a consequence of CCL2 neutralization.
The apparent discrepancy between these results and ours
can be, at least in part, explained by the different protocol
used for monocyte culture, which may greatly influence
the ability of MDM to activate innate immune reactions
and support HIV-1 replication. To this regard, it has been
recently shown that MDM generated in the presence of
M-CSF are more permissive to HIV-1 replication, but
paradoxically have a strongest innate immune response
[78]. Furthermore, additional studies pointed to an up-
regulated expression of A3A as the causal factor of the
restriction of HIV-1 replication elicited by different condi-
tions in myeloid cells [53,79-81]. In particular, exposure to
exogenous type I IFNs, or to the type I IFN-inducing cyto-
kine IL-27, has been shown to stimulate A3A expression
in both macrophages and DCs and to inhibit HIV-1 repli-
cation in the former and viral spread to CD4+ T cells in
the latter [79,80]. In macrophages, treatment with IFN-α
resulted in a strong induction of A3A expression and
reduction of HIV-1 DNA accumulation, associated with
an increased G-to-A editing of viral DNA [53]. Finally,
Cassetta and co-workers reported that restriction of
HIV-1 replication in M1 polarized macrophages was
associated with the up-regulated expression of A3A, but
not A3G [81].
Although in this study we demonstrate that CCL2
neutralization impairs HIV-1 DNA accumulation, the
cellular factors that sustain this inhibition remain to be
identified and the mechanisms deciphered. Keeping in
mind the effect on viral DNA accumulation, a role for
host restriction factor(s) affecting this step of the HIV-1
life cycle might be suggested. In this regard, we excluded
the involvement of SAMHD1 in this phenomenon. In
fact, our data strongly indicate that neither altered
SAMHD1 expression nor function likely account for
Sabbatucci et al. Retrovirology  (2015) 12:4 Page 16 of 22the restriction of HIV-1 replication mediated by CCL2
neutralization. Although SAMHD1 has been shown to
reduce the pool of dNTPs thus inhibiting the reverse
transcription step especially in myeloid cells, a recent
study reported that this factor moderately restricts a
macrophage-tropic HIV-1 strain in MDM, whereas it
potently inhibits HIV-1 replication in undifferentiated
monocytes [82]. In accordance with this report, it has
been shown by other groups that SAMHD1 is not a major
effector of the early type I IFN-mediated block toward
HIV-1 [57,83]. Furthermore, our data indicate that CCL2
blocking does not affect the expression of Mx2, recently
shown to restrict HIV-1 replication by inhibiting the
nuclear accumulation and integration of HIV-1 reverse
transcripts [61]. Conversely, we found a strong association
between CCL2 neutralization-mediated inhibition of
HIV-1 replication and induction of A3A expression.
Interestingly, the levels of A3A expression elicited by
CCL2 blocking in MDM are comparable to those of
freshly isolated monocytes, where this enzyme has been
demonstrated to restrict HIV-1 infection [42]. In keeping
with these data, other groups reported that inhibition of
HIV-1 DNA accumulation in myeloid cells was corre-
lated to A3A expression in different conditions [53,81].
However, since our efforts to deplete A3A protein in anti-
CCL2 Ab-treated MDM using siRNA have not been
successful, as already experienced by other groups in dif-
ferent experimental settings [53,84], we could not formally
prove the involvement of this protein in the observed
inhibition of viral replication. Thus far, we cannot rule out
the possibility that other not yet identified factors may be
involved in the restriction of HIV-1 replication elicited by
CCL2 blocking. In this regard, our data show that other
genes related to the defense response to viruses are
upmodulated in MDM exposed to anti-CCL2 Ab, thus
suggesting that several factors might contribute to the
restriction of HIV-1 replication elicited by CCL2 neutra-
lization. Future work is required to define whether the
CCL2 blocking-mediated inhibition of HIV-1 replication
in MDM is associated or not with an increased G-to-A
editing of viral DNA and/or with others mechanisms of
HIV-1 restriction.
Conclusions
Neutralization of macrophage-derived CCL2 potently
restricts HIV-1 replication by inhibiting early post-entry
steps of the viral life cycle. Since macrophages represent
potential viral reservoirs capable of producing replication-
competent HIV-1 virions even in the presence of effective
combination antiretroviral therapy, targeting CCL2 may
represent a novel therapeutic strategy for enhancing cellu-
lar defences against HIV-1 and protecting macrophages
from infection. Interestingly, enhanced CCL2 expressionhas been also found in ectocervical tissue explants follow-
ing HIV-1 infection, and neutralization of the chemokine
in this experimental system has been shown to result in
viral transcription decrease [85]. Thus, since the hetero-
sexual route through female reproductive tract mucosal
surfaces is the predominant mode of HIV-1 transmission,
targeting CCL2 may offer a tantalizing possibility of lever-
aging innate immunity to fend off viral infection at the
entry route.
Methods
Ethics statements
Healthy donor Buffy coats were obtained from Centro
Trasfusionale-University of Rome “Sapienza”. Buffy coats
were not obtained specifically for this study. Informed con-
sent has not been asked because data were analyzed an-
onymously. Data from healthy donors have been treated by
Centro Trasfusionale according to the Italian law on per-
sonal data management “Codice in materia di protezione
dei dati personali” (Testo unico D.L. June 30, 2003 n. 196).
Cell separation and culture
Monocytes were isolated from peripheral blood mono-
nuclear cells obtained from healthy donor Buffy-coats by
positive immunomagnetic selection using CD14 micro
beads (MACS monocyte isolation kit, Miltenyi Biotec),
according to the manufacturer’s instructions. This pro-
cedure yields a 95-98% pure population of monocytes, as
assessed by fluorescence-activated cell sorter analysis
of lineage-specific surface markers (CD1a, CD14, CD3,
CD19, and CD56). Freshly isolated monocytes were
seeded in 48-well cluster plates (1x106 cells per well in
1 ml) and cultured for 6 days in endotoxin-free IMDM
(Life Technologies) containing 10% FBS to obtain MDM
as previously described [69].
Reagents
Rabbit polyclonal and mouse monoclonal Abs directed
against CCL2 and CCL3, respectively, as well as control
rabbit and mouse Abs, were purchased from PeproTech.
Goat anti-CCL4, anti-CCL5 and control Abs were pur-
chased from R&D Systems. At the concentration em-
ployed in the study, the anti-CCL3 and anti-CCL5 Abs
effectively neutralized the endogenously produced che-
mokines, whereas the anti-CCL4 Ab inhibited CCL4-
mediated ERK1/2 phosphorylation, as assessed by Elisa
and western blot, respectively (data not shown). Recom-
binant human IFN-β and IFN-α were kindly provided by
Serono and Schering-Plough, respectively. Sheep anti-
human IFN-α (neutralizing titer is 1:3000000 against 8
units IFN-α) and calf anti-human IFN-β (neutralizing titer
is 1:25000 against 10 units IFN-β) sera were kindly pro-
vided by Dr Vilcek. In a cytopathic effect reduction assay
these sera have been shown to neutralize exogenous IFNs
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LDLR was purchased from R&D Systems. The nucleoside
analogue reverse-transcriptase inhibitor AZT and the
fusion inhibitor T20 were obtained from the National
Institutes of Health AIDS Research and Reference Reagent
Program.
Viruses and infection
HIV-1 preparations pseudotyped with VSV-G were ob-
tained from the supernatants of 293 T cells 48 h after
cotransfection with a vector expressing VSV-G under
the control of CMV immediate-early promoter and a
vector expressing pdeltaEnvNL4-3 HIV-1 in a molar
ratio of 1:5. Cotransfection was performed using Lipo-
fectamine 2000 (Invitrogen). Supernatants were clarified
and concentrated by ultracentrifugation as previously
described [86]. For lentiviral preparations a total of 12 μg
of plasmid DNA were used for each plate in a ratio 6:4:2
(transfer vector: packaging vector: VSV-G vector). The
plasmids pCMVdR8.2, the VSV-G envelope expressing
pMD.G plasmid and the pTY2-CMV-GFP-W transfer
vector have been already described [87-89]. For construc-
tion of SIV-Vpx expressing plasmid, Vpx derived from the
SIVMAC251 strain was modified [90] and 10 μg of this
plasmid were included in the transfection. 293 T cells were
transiently transfected with the calcium phosphate-based
protocol using the Calcium Phosphate-based Profection
Mammalian Transfection System (Promega Corporation)
and the supernatants were clarified and concentrated by
ultracentrifugation as previously described [88]. VSV-G
pseudotyped HIV-1 preparations were titrated in terms of
HIV-1 CAp24 content using quantitative enzyme-linked
immunosorbent assay (ELISA; Innogenetics), whereas len-
tiviral titres were normalized by RT [91]. Infection with
pseudotyped HIV-1 derivatives was achieved by spinocula-
tion at 400 × g for 30 min at room temperature using
250 ng CAp24 equivalent of (VSV-G) HIV-1 per 105 cells
or 2×106 TU of LV/Vpx per 106 cells, respectively. Virus
adsorption was prolonged for an additional 3 h at 37°C
and the cells were washed and re-fed with complete me-
dium. Cells were analyzed 3 days post-infection.
For VLP preparations, 293/RGP cells [92] were co-
transfected by liposomes (Lipofectamine 2000) with
the immediate-early CMV promoter vector expressing
NefG3C-GFP alone or in combination with vectors ex-
pressing VSV-G or R5 Env HIV-1 from the Ada isolate.
After 6 h, cells were induced with 5 mM sodium bu-
tyrate (Sigma-Aldrich) and 2 μM of Ponasterone A
(PonA) (Sigma-Aldrich) for 24 h. Supernatants were then
replaced with fresh medium containing the inducers.
VLP-containing supernatants were harvested from 48 to
72 h later, clarified, and concentrated by ultracentrifu-
gation on 20% sucrose cushion at 100,000 g for 2 h at 4°C.
VLP preparations were titrated by measuring the HIV-1CAp24 contents by quantitative ELISA (Abbott, Abbott
Park). For MDM challenge, VLPs (1 μg of CAp24
equivalent per 105 cells) were absorbed by spinocula-
tion at 150 g for 30 min at room temperature or at 4°C.
Afterwards, the cell cultures were re-fed by adding fresh
medium, and incubated at 37 or 4°C. After 2 or 4 h, the
cells were treated for 15 min with trypsin at 37 or 4°C,
fixed, and analyzed by flow cytometry. Representative
images were taken by the EVOS FL Cell Imaging System
(Life Technologies) and by the Leica TCS SP2 AOBS ap-
paratus (Leica Microsystemsy) for the confocal laser-
scanner microscopy analysis.
For productive infection, cells were infected with the
Vif+ CCR5-dependent HIV-1BaL strain (3000 TCID50 per
well; Advanced Biotechnologies). After 2 h, cells were
washed and maintained in complete medium either in
the presence or in the absence of anti-CCL2 or control
Ab. Medium was replaced with fresh medium every 7 days.
Abs were added twice a week. In some experiments,
infected MDM were treated with dNTPs (Pharmacia)
once a week.
ELISA
The levels of CCL2 present in culture supernatants were
measured by ELISA kits purchased from R&D Systems
(detection limit 5 pg/ml). Viral production was moni-
tored by measuring HIV-1 p24 Gag Ag release by the
INNOTEST HIV Antigen mAb kit (Innogenetics).
Flow cytometry analysis of p24 Gag Ag
MDM were detached by using 0.05% trypsin-EDTA so-
lution, and intracellular HIV-1 p24 Gag expression was
evaluated by flow cytometry. Briefly, cells were fixed and
permeabilized by using Fixation and Permeabilitazion
Buffers (eBioscience). Cells were then labelled with a
Phycoerythrin-conjugated monoclonal Ab specific for
p24 Gag (KC57-R01, Coulter Clone) and washed with
Permeabilization Buffer. The background fluorescence
was determined by labelling uninfected cells. Samples
were acquired with a FACS Calibur flow cytometer by
using Cell Quest (Becton Dickinson) and data analyzed
by FlowJo (Tree Star, Inc.) or the Cell Quest software.
Analysis of HIV-1 DNA synthesis during early phase of
transcription by polymerase chain reaction
A semi-quantitative PCR assay was used to estimate the
extent of reverse transcription at three replicative steps:
R-U5, initial minus strand synthesis; R-PB, initial plus-
strand synthesis up to the PB region; and R-gag, complete
minus-strand synthesis. The primers used to amplify these
products were M667/AA55 (R-U5) producing a 140 bp
amplicon, M667/BB301(R-PB) producing a 156 bp ampli-
con, and M667/M661 (R-gag) producing a 200 bp
amplicon (M667, 5′-GGCTAACTAGGGAACCCACTG-
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BB301, 5′-CCCTGTTCGGGCGCCACTG-3′; M661, 5′-
CCTGCGTCGAGAGAGCTCCTCTGG-3′). DNA load for
each PCR amplification was the same and it was normal-
ized by Real Time PCR quantitative amplification of
RNase P gene using TaqMan RNase P Detection Reagents
Kit (Applied Biosystems) according to manufacturer’s
instructions. Quantization of HIV-1 DNA during PCR
amplification was performed by analyzing a standard
curve of serial dilutions of HIV plasmid pHxb2 ranging
from 1 to 1x105 copies. PCR conditions were: 95°C, 3 min;
95°C, 30 s; 60°C, 30 s; 72°C, 30 s, for 35 cycles.
The quantitative analysis of HIV-1 intermediate
reverse-transcript products was performed by SYBR
Green real-time PCR of minus-strand strong-stop DNA
using M667/AA55 primers and of 1st template switching
of RT using M667/BB301 primers. A standard curve was
generated using serial dilution ranging from 10,000 to 1
copy of pHxb2 plasmid containing the full length se-
quence of HIV. Each primer was used at a final concentra-
tion of 200 nM. The PCR parameters were as follows:
20 sec at 95°C followed by 40 cycles at 95°C for 15 sec and
60°C for 1 min. Fluorescent product was detected at the
last step of each cycle. After amplification a melting curve
was generated. All samples and HIV-1 negative controls
were run in duplicate.
Quantification of HIV-1 DNA by real-time polymerase
chain reaction
Total DNA was extracted from frozen MDM samples
using the QIAamp DNA Blood Mini kit (Qiagen) accord-
ing to the manufacturer’s instructions; in each extraction
uninfected cells were included as negative control. The
concentration of the extracted DNA was determined by
Real Time PCR quantitative amplification of RNase P gene
using TaqMan RNase P Detection Reagents Kit (Applied
Biosystems) according to manufacturer’s instructions.
Total HIV-1 DNA amount was determined using primers
and probe that recognize the HIV-1 gag gene [93]. Stand-
ard curve was generated using the genomic DNA from
the 8E5 cell line, a T lymphoblastoid cell line that contains
a single defective copy of HIV-1 genome per cell.
Integrated HIV DNA was quantified by a two-step
Alu-gag PCR assay. The first PCR was performed in trip-
licate for each sample, using two primers annealing to
Alu sequences (AluFw 5′-GCCTCCCAAAGTGCTGGG
ATTACAG-3′; AluS 5′-TCCCAGCTACTGGGGAGGCT
GAGG-3′; final concentration: 100nM each) and one
primer annealing to gag gene (HIV-gag Rev nt 1505–
1486: 5′- GTTCCTGCTATGTCACTTCC-3′; final con-
centration: 600nM). Samples were amplified in triplicate
also with the HIV-gag Rev primer alone (gag-only PCRs)
in order to establish whether the level of integration is
detectable (see below). Standard curve was generatedusing serial dilutions of genomic DNA extracted from a
standard cell line prepared as previously described [94].
The number of HIV proviruses per cell of the standard
cell line was calculated with the same procedure used to
calculate total HIV-1 DNA and then adjusting the result
by the number of assayed cells calculated by RnaseP
gene quantification. The standard curve ranged from
10,000 to 1 integrated HIV-1 copies per well. To keep
the number of Alu DNA sites constant in each reaction,
uninfected PBMC genomic DNA was added to each
sample (including standards and controls) to reach the
concentration of 70 ng of genomic DNA per well. The
parameters for the first PCR were as follows: 10 min at
95°C followed by 25 cycles at 95°C for 15 sec, 50°C for
15 sec and 72°C for 3 min and 30 sec and finally 5 min
at 72°C. The second real-time PCR step detects HIV-
specific products by using primers annealing to the R
and U5 regions within the HIV LTR: RU5 R forward
(5′-TTAAGCCTCAATAAAGCTTGCC-3′), RU5 U5 re-
verse (5′-GTTCGGGCGCCACTGCTAGA-3′) and RU5
Probe (5′- CCAGAGTCACACAACAGACGGGCACA-3′);
this real-time PCR was performed on 5 ul from each repli-
cate of both Alu-gag and gag-only PCRs of standard curve
and unknown samples. The PCR parameters were as
follows: 3 min at 95°C followed by 45 cycles at 95°C for
3 sec and 60°C for 30 sec. Student’s t-test was performed
to determine whether Cts derived from the Alu-gag PCRs
were significantly lower than those from the gag-only reac-
tions. If Alu-gag Cts are statistically lower than gag-only
Cts (p < 0.05) for the same sample, HIV-1 integrated cop-
ies can be calculated with reference to the standard curve.
Otherwise, the level of integration is to be considered
below the limit of detection of the assay [94].
The 2-LTR DNA circles were quantified by SYBR
Green real-time PCR and amplified from extracted DNA
with 25 nM forward primers HIV-F (5′-TGTGCCCGTC
TGTTGTGTGACT-3′) and 25 nM reverse primer HIV-
R1 (5′-TGGTGCTACAAGCTAGTACCAGT-3′) spanning
the LTR–LTR junction (modified protocol from Reigadas
S et al.) [95]. A plasmid containing the 2-LTR junction
sequence was used to generate the standard curve (ran-
ging from 10,000 to 1 copy) for 2-LTR DNA circles
quantification; each curve point was obtained diluting
the plasmid DNA in 50 ng of genomic DNA from HIV
negative donors PBMCs. The PCR parameters were as
follows: 20 sec at 95°C followed by 45 cycles at 95°C for
3 sec and 62°C for 1 min. Fluorescent product was de-
tected at the last step of each cycle. After amplification a
melting curve was generated. All samples and HIV-1
negative controls were run in triplicate. Rnase-P, HIV-1
gag and HIV-1 2LTR standard curves had slopes be-
tween −3.15 and −3.6 and the coefficients of correlation
was >0.987. HIV-1 DNA load and HIV-1 2-LTR circles
load were normalized to the amount of cellular DNA by
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number of copies/106 cells. The limit of detection was 2
copies/106 cells for total HIV-1 DNA and 200 copies/106
cells for HIV-1 2-LTR circles. The ABI Prism 7500 FAST
Real time PCR System (Applied Biosystem) was used for
PCR amplification, acquisition and data analysis.
RNA isolation and polymerase chain-reaction
Total RNA was isolated with the RNeasy Mini kit
(Qiagen) following the manufacturer’s instructions. RNA
was retrotranscribed into cDNA by using poly d(N)6
(GE Healthcare) and real-time PCR was performed
as previously reported [96]. Validated PCR primers
and TaqMan MGB probe (6FAM-labeled) for A3A
(Hs00377444), A3B (Hs.PT.53a.20328233), A3C (Hs.
PT.53a.4514833), A3D (Hs.PT.53a.4652525), A3F (Hs.PT.
53a.27075498), A3G (Hs.PT.49a20797403), A3H (Hs.PT.
53a.3752998), SAMHD1 (Hs.PT.49a.21502281) and Mx2
(Hs.PT.58.21491026) were used (A3A from Applied
Biosystem, A3B-H, SAMHD1 and Mx2 from Integrated
DNA Technologies). As endogenous control, primers
and TaqMan probe for the human β-actin (ACTB RNA;
Hs99999903_m1; Applied Biosystems) were used. Thermal
cycler conditions were previously reported [96]. Relative
quantification was performed by using the comparative
Ct method as previously described [96].
RNA sequencing and differential expression analysis
RNAs were collected individually from 2 donors (two
20 h CTR and two 20 h anti-CCL2 Ab). RNAseq librar-
ies were created with the Illumina Truseq RNA sample
pre kit and sequenced using the Illumina Hiseq 2500
platform. These 4 samples were sequenced 3 times in
multiplexed lanes. Reads of the same sample from 3 runs
were pooled together.
Tophat [97] (Version 2.0.6) together with bowtie (ver-
sion 0.12.8) were used to align reads to human genome
GRCh37/hg19 with Ensembl 75 gene annotation. Only
uniquely mapped reads were used to count reads aligned
to each gene. The reads were quantified by htseq-count
[98] (version 0.5.3p9) with Ensembl 75 gene sets. Gene
differential expression analysis was performed using
DESeq2 [58] (version 1.4.5). Genes which had no reads
across all samples were discarded. Genes with and with
more than a two-fold change in expression and an adjus-
ted p-value of less than 0.1 were classified as significantly
differentially expressed.
Western blot analysis
Freshly isolated monocytes and MDM were lysed in
radio immunoprecipitation assay buffer [150 mM NaCl,
50 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 0.5% sodium
deoxicholate, 0.1% sodium dodecyl sulphate (SDS)] con-
taining the complete protease inhibitor cocktail (RocheMolecular Biochemicals). Protein concentrations were
determined by protein assay (Bio-Rad Laboratories).
Cell lysates (10–20 μg per lane) were fractionated on
8-12% SDS-PAGE, electroblotted to nitrocellulose filters
(Protran BA 85, Schleicher & Schuell), and probed with
Abs anti-human A3A (rabbit polyclonal D23, Santa Cruz
Biotechnology), anti-human A3G (goat polyclonal 109727,
Abcam), anti-human SAMHD1 (rabbit polyclonal 366–
380, Sigma-Aldrich), anti-human Mx2 (goat polyclonal
N17, Santa Cruz Biotechnology) and anti-actin (mouse
monoclonal Abs-5, BD Biosciences) as gel loading control.
The anti p-SAMHD1 T592 Ab has been previously de-
scribed [99]. SuperSignal West Femto Substrate (Pierce)
and ECL Western blot detection Reagent (Amersham)
were used according to the manufacturer’s instructions.
Levels of A3A and Mx2 proteins were quantified using a
GS-800 Calibrated Densitometer (Bio-Rad Laboratories).
Statistical analysis
Data analysis was performed by using the Microsoft
Office Excel 2007 software. Results are reported as
means ± SE. Comparison between two groups was per-
formed using paired, two-tailed t test. Values of p < 0.05
were considered statistically significant.
Additional files
Additional file 1: Figure S1. MDM-derived CCL2 is effectively
neutralized by anti-CCL2 Ab. MDM were treated with anti-CCL2 or control
Ab (2.5 μg/ml) for 20 h and then infected with HIV-1BaL (A) or (VSV-G)
HIV-1 (B) as described in Methods. Supernatants were collected at 14 or
3 days post-infection, respectively, and the content of CCL2 was
measured by ELISA. In A, data represent mean values (+SE) of the results
obtained with 6 donors analyzed. In B, the results from 1
representative donor out of 2 tested are shown.
Additional file 2: Figure S2. Endogenous CCL2 neutralization does not
affect entry of HIV-1-based VLPs in MDM. MDM were treated with anti-CCL2
or control Ab (2.5 μg/ml) for 20 h and then challenged with VSV-G-VLP or
Ada-VLP (1 μg of CAp24 equivalent per 105 cells) as described in Methods.
After 2 h, the percentage of GFP+ cells was assessed by flow cytometry. The
flow cytometry histograms of 1 of the donors reported in Figure 2A are
shown.
Additional file 3: Figure S3. Endogenous CCL2 neutralization does
not affect HIV-1 DNA intermediates synthesis. MDM were treated with
anti-CCL2 or control Ab (2.5 μg/ml) for 20 h and then infected with
HIV-1BaL as described in Methods. Total DNA was extracted 24 h after
infection and the levels of HIV-1 DNA intermediates (early, partial reverse
and full-length transcripts) were assessed by semi-quantitative PCR (A) or
quantitative Real Time PCR (B). The results from 1 representative donor
out of 2 tested are shown.
Additional file 4: Figure S4. Neutralization of endogenous CCL2
impacts the kinetic of HIV-1 DNA accumulation in MDM. MDM were
treated with anti-CCL2 or control Ab (2.5 μg/ml) for 20 h and then
infected with HIV-1BaL as described in Methods. Total DNA was extracted
4 and 7 days after infection and the amount of total HIV-1 DNA (copies/
106 cells) was determined by qPCR. In A, the results from 1 representative
donor out of 4 tested are shown. In B, data represent mean values (+SE)
of the results obtained with all the donors analyzed.
Additional file 5: Figure S5. Exogenous dNTPs supplementation
increases the percentage of p24 Gag+ MDM. MDM were treated with
Sabbatucci et al. Retrovirology  (2015) 12:4 Page 20 of 22anti-CCL2 or control Ab (2.5 μg/ml) for 20 h and then infected with
HIV-1BaL (3000 TCID50 per well) either in the absence or in the presence
of dNTPs as described in Methods. After 14 days, cells were recovered
and HIV-1 Gag expression was evaluated by flow cytometry. The results
from 1 representative donor out of 4 tested are shown.
Additional file 6: Figure S6. Neutralization of endogenous CCL2 does
not induce A3G expression in MDM. MDM were treated with anti-CCL2
or control Ab (2.5 μg/ml) or IFN-β (1000 U/ml). After 20 h, cells were lysed
and A3G protein expression in whole cell extracts was detected by western
blot. Actin was used as house-keeping control. The result from one
representative experiment of 3 independently performed is shown.
Additional file 7: Figure S7. A3A expression is not affected by
challenge with LV/Vpx in MDM. MDM were treated with anti-CCL2 or
control Ab (2.5 μg/ml) for 20 h and then challenged or not with LV/Vpx
as described in Methods. After 3 days, cells were lysed and A3A protein
expression in whole cell extracts was detected by western blot. Actin was
used as house-keeping control. The result from one representative donor
out of 2 tested is shown.
Additional file 8: Table S1. Differential expression analysis of genes
modulated by CCL2 neutralization in MDM.
Additional file 9: Table S2. Functional annotation clustering by DAVID
of the 194 genes upregulated by CCL2 neutralization in MDM.
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